OBJECTIVES : New evidence in hematologic cancers is continuously being published. As a result, conventional SLRs that are updated annually may miss considerable relevant new evidence. Within a living SLR platform (LiveSLR), updates of clinical, economic, and health-related quality of life (HRQoL) SLRs in ND AML and RR ALL were conducted monthly over a 6-month period.

METHODS : Updates were performed within an in-web based LiveSLR platform, using PRISMA guidelines and utilizing search strategies from original SLRs. EMBASE, MEDLINE, and Cochrane (12/2019–06/2020) databases, and five scientific congresses (EBMT, AMCP, ISPOR, ASCO, EHA), were reviewed. The updates were conducted in ND AML eligible for intensive chemotherapy (IC-AML) and NIC-AML, as well as RR ALL.

RESULTS : In the original SLR (01/2000-11/2019), 139 (IC-AML) and 112 studies (NIC-AML) were included, respectively, in ND AML, including 76 and 44 randomized clinical trials (RCTs), 47 and 44 economic as well as 17 and 24 HRQoL studies. Following 6 months of LiveSLR updates, 1,143 (IC-AML) and 619 (NIC-AML) records were reviewed, of which 36 and 26 studies were included. Within these studies, 9 original RCTs, 12 economic, and 9 HRQoL studies were included for IC-AML, while 11 original RCTs, 7 economic, and 3 HRQoL studies were included for NIC-AML. For the SLR in RR ALL, a total of 51 studies were included in the original SLR (01/2009–10/2019), including 18 clinical trials, 24 economic, and 9 HRQoL studies. After 6 months of updates, 572 records were reviewed, of which 18 studies met the inclusion criteria (9 clinical, 8 economic, and 1 HRQoL).

CONCLUSIONS : Considering the accelerated pace of data production and publication within the scope of hematologic cancers, continuous updates via a LiveSLR platform can address key challenges in capturing immediate evidence relevant for decision-making.